Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.42 EPS.

SGMO has been the topic of a number of other reports. Truist Financial lowered their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company cut their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. Jefferies Financial Group decreased their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, Barclays upped their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Stock Performance

SGMO opened at $1.13 on Monday. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The company has a market cap of $235.77 million, a PE ratio of -1.51 and a beta of 1.29. The company has a 50 day moving average of $1.76 and a 200 day moving average of $1.33.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. During the same period last year, the company earned ($0.34) earnings per share. Research analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares in the last quarter. Golden State Equity Partners lifted its stake in Sangamo Therapeutics by 2,592.3% in the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 313,587 shares during the last quarter. Geode Capital Management LLC boosted its position in Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after buying an additional 272,123 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Sangamo Therapeutics during the second quarter valued at about $89,000. Finally, Vontobel Holding Ltd. increased its holdings in shares of Sangamo Therapeutics by 412.3% in the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 241,440 shares during the period. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.